Učitavanje...
ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design
This article is a Commentary on Boengler K, Bulic M, Schreckenberg R, Schlüter K‐D, Schulz R (2017). The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. Br J Pharmacol 174: 2060–2073. https://doi.org/10...
Spremljeno u:
| Izdano u: | Br J Pharmacol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513857/ https://ncbi.nlm.nih.gov/pubmed/28567717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13891 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|